Holding
In Nanofiber Solutions, LLC v. Acera Surgical, Inc.,
IPR2021-01016, Paper 8 (P.T.A.B. Dec. 13, 2022), the Patent Trial
and Appeal Board ("the Board") found claims 1, 2, 4-7,
and 13 of Acera's US Pat. No. 10,632,228 ("the '228
patent") unpatentable. The Board also held that Nanofiber did
not establish by a preponderance of the evidence that claims 3,
8-12, or 14-20 of the '228 patent are unpatentable.
Background
The '228 patent describes using non-woven graft materials,
comprising at least two distinct fiber compositions, to repair
tissue following surgical procedures. '228 patent at 1:6-13.
The claims recite the use of poly(glycolic acid) (PGA) and
poly(lactide-co-caprolactone) (PLCL) as the two fiber compositions.
Id. at 19:45-46, 56-59.